Canada’s Cannabis Export Market Hits $900 Million as Global Demand Accelerates
Canada’s cannabis industry has found its salvation abroad. Health Canada data released this week shows that Canadian licensed producers exported $897 million worth of cannabis products in 2025 — a 92% increase from $467 million in 2024 and the strongest signal yet that international markets are becoming a primary growth engine for Canada’s embattled domestic industry.
The export boom comes at a critical moment. Canada’s domestic cannabis market has been mired in oversupply, price compression, and a wave of bankruptcies that has claimed dozens of licensed producers since legalization in 2018. For the survivors, international markets represent not just incremental revenue but existential relevance.
Where Canadian Cannabis Goes
Germany is the dominant export destination, absorbing approximately 42% of Canadian cannabis exports by value. Germany’s cannabis social club model — launched in April 2024 — has created institutional demand for pharmaceutical-grade dried flower and extracts that German domestic production cannot yet meet. Canadian producers, with six years of regulatory compliance experience and GMP-certified facilities, are the natural suppliers.
Australia represents the second-largest market at 18% of exports. Australia’s medical cannabis program has grown steadily, and the country’s pharmaceutical import framework — which requires products to meet Therapeutic Goods Administration standards — favors established Canadian producers with proven quality systems. Canopy Growth, Tilray, and Aurora Cannabis have all expanded their Australian distribution partnerships in the past 12 months.
Israel accounts for 14% of exports, driven by the country’s large and growing medical program. The United Kingdom, Poland, and several Latin American countries make up the remaining 26%, with the UK showing the fastest growth rate among secondary markets.
Product Mix
The export product mix differs significantly from Canada’s domestic market. Medical-grade dried flower accounts for 55% of export value — a much higher share than the domestic market, where recreational consumers have shifted toward vapes and edibles. Cannabis oils and extracts represent 30%, and pharmaceutical preparations (standardized dose formulations) account for 15%.
The pharmaceutical category is particularly significant because it commands the highest margins. Standardized dose products — such as capsules with precise THC/CBD ratios — sell at 3-4x the price per milligram of THC compared to bulk flower, reflecting the value-add of pharmaceutical formulation and the regulatory requirements of importing countries.
Canadian producers have invested heavily in GMP certification and EU-GMP compliance to access these premium export channels. The cost of maintaining GMP facilities is substantial — estimated at $2-5 million annually for a mid-size producer — but the margin differential makes international pharmaceutical-grade sales among the most profitable segments in the entire cannabis industry.
Impact on Canadian Producers
The export boom has created clear winners among Canadian licensed producers. Tilray, which operates the largest EU-GMP-certified cannabis facility outside of Europe, reported that international sales accounted for 38% of its cannabis revenue in Q4 2025, up from 19% a year earlier. Aurora Cannabis, which had pivoted to a medical and international focus after struggling in the domestic recreational market, now generates over 50% of its cannabis revenue from exports.
Smaller producers are also benefiting, though access to export markets requires regulatory capabilities that many lack. Companies like Organigram and HEXO have partnered with international distributors to access markets they couldn’t enter independently, creating a two-tier structure where large producers export directly while smaller operators sell through intermediaries.
The financial impact is meaningful. Canadian cannabis company stock prices have outperformed the broader cannabis index in 2026, driven largely by international revenue growth. Several producers that were on the verge of insolvency in 2024 have stabilized their balance sheets through export contracts.
Challenges and Risks
The export market is not without risks. Regulatory changes in importing countries can disrupt trade flows overnight. Germany’s domestic cultivation program, which is scaling slowly but steadily, will eventually reduce demand for Canadian imports. And competition from other exporting countries — including Uruguay, Colombia, Portugal, and increasingly, African nations like Lesotho and South Africa — is intensifying.
Quality and compliance remain differentiators for Canadian producers, but cost competition is growing. Colombian producers can cultivate cannabis at a fraction of Canadian costs, and several have obtained EU-GMP certification in the past year. As more low-cost producers achieve regulatory compliance, the price premium that Canadian cannabis commands internationally will erode.
For the U.S. cannabis industry, which remains locked out of international markets by federal prohibition, Canada’s export success is both instructive and frustrating. If federal reform eventually enables U.S. cannabis exports, American producers would enter a global market that Canadian companies have spent years developing — a first-mover advantage that could prove durable.